(Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted ...

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult ...

The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor ...

Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of n ...

GSK plc announced positive headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter ...

Cholestatic pruritus is a common symptom of primary biliary cholangitis (PBC), a rare autoimmune liver disease. Researchers are looking to establish the safety and efficacy of linerixibat – an ...

Treatment with liberixibat led to a statistically significant improvement in itch compared with placebo. Topline results were announced from a phase 3 trial evaluating linerixibat for the ...

(Getty Images) Among 227 adult participants at baseline, 42% had moderate pruritus and 58% had severe pruritus. The most common prior pruritus therapies were antihistamines (15%), bile acid-binding ...

"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data ...

Data presented at The Liver Meeting include adverse events as well as an assessment of patients’ relief of pruritus symptom scores when correlated to pharmacokinetics of TH104. Patients with ...